BC Innovations | Feb 28, 2017
Distillery Techniques

Assays and screens

TECHNOLOGY: Cell-free assays A synaptosome-based assay of long-term synaptic potentiation could be used to screen therapies to treat AD. The assay involved isolating synaptosomes from frozen, postmortem parietal cortex samples from AD patients and unaffected...
BC Week In Review | Aug 13, 2012
Company News

Sigma-Aldrich, Autism Speaks deal

Sigma-Aldrich's Sigma Advanced Genetic Engineering (SAGE) Labs initiative and the advocacy group expanded a 2010 deal to develop rat models with modified autism-associated genes. Under the expansion, the partners will generate rat knockout models with...
BC Innovations | Jun 24, 2010
Targets & Mechanisms

Common ground in autism and epilepsy

A pair of studies has identified rare genomic copy number variants associated with both autism and epilepsy, suggesting there might be common mechanisms behind both diseases. 1,2 The most immediate application of the findings could...
BC Innovations | Jul 16, 2009
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Autism Benzodiazepine receptor (peripheral)-associated protein 1 (BZRAP1); MAM domain containing glycosylphosphatidylinositol anchor 2 (MDGA2); contactin 4 (CNTN4); neurexin 1 (NRXN1) A genomewide study suggests that...
BC Innovations | May 7, 2009
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Autism Astrotactin 2 (ASTN2); constitutive photomorphogenic 1 (RFWD2; COP1); contactin 4 (CNTN4); F-box protein 40 (FBXO40); neuroligin 1 (NLGN1); neurexin 1...
Items per page:
1 - 5 of 5